DaVita Inc. (NYSE:DVA) Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 53.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,229 shares of the company's stock after selling 5,913 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in DaVita were worth $782,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in DVA. SBI Securities Co. Ltd. purchased a new stake in shares of DaVita during the 4th quarter worth approximately $41,000. Quarry LP purchased a new stake in DaVita in the third quarter valued at $60,000. Venturi Wealth Management LLC boosted its stake in DaVita by 59.8% in the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock valued at $61,000 after acquiring an additional 152 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of DaVita by 58.7% during the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company's stock worth $68,000 after purchasing an additional 169 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of DaVita by 39.7% during the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after purchasing an additional 131 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DVA has been the subject of a number of research analyst reports. StockNews.com cut DaVita from a "buy" rating to a "hold" rating in a research report on Friday. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. Finally, Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, DaVita has an average rating of "Hold" and an average price target of $166.33.

Remove Ads

DaVita Stock Performance

Shares of NYSE:DVA traded up $0.19 during trading on Tuesday, reaching $150.60. The company had a trading volume of 662,227 shares, compared to its average volume of 783,786. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. The stock's fifty day moving average price is $158.40 and its 200 day moving average price is $157.57. The firm has a market capitalization of $12.05 billion, a price-to-earnings ratio of 14.02, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. As a group, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.